智通财经APP获悉,随着市场对诺和诺德(NVO.US)旗下Wegovy和礼来(LLY.US)旗下Zepbound这类减肥药的需求激增,人们对这类药物可能带来的肌肉质量下降这一重大风险的担忧也有所加剧。越来越多的生物技术公司正在竞相解决这个问题。据悉,Wegovy和Zepbound等GLP-1类药物在减重方面拥有显著的效果,但这种减重很大程度上减的是肌肉量。当减少卡路里的摄入时,不仅脂肪会减少,肌肉...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.